Related Experiment Video
Updated: May 5, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Glycolytic reprogramming during microglial polarization in neurological diseases
Xiaoting Li1,2, Congcong Fang3, Yina Li1,2
1Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, China.
Background:
Microglia, the resident immune cells of the central nervous system (CNS), play pivotal roles in the onset and progression of various neurological disorders. Owing to their remarkable plasticity, microglia can adopt diverse phenotypic states in response to distinct microenvironmental cues. Over the past decades, accumulating evidence has demonstrated that immune cell metabolism critically regulates their polarization and effector functions through a process termed metabolic reprogramming, in which glucose metabolism is particularly central. Glycolytic reprogramming underlies the entire polarization process, and elucidating its mechanisms may enable targeted modulation of microglial activity to mitigate their deleterious effects in CNS pathologies, thereby offering novel therapeutic avenues for these diseases.
Aim Of The Review:
This paper summarizes what is known about microglial polarization and glycolytic reprogramming and explores their important roles in the development of neurological diseases. The link between microglial metabolomics and epigenetics in neurological disorders requires further study.
Key Scientific Concepts Of The Review:
Microglia exhibit distinct phenotypic states at different stages of central nervous system (CNS) disorders, and these polarization processes are closely coupled with glucose metabolic reprogramming. Proinflammatory microglia predominantly rely on glycolysis, whereas reparative or anti-inflammatory phenotypes primarily utilize oxidative phosphorylation. Targeting glycolytic pathways to limit the polarization of microglia toward proinflammatory states has emerged as a promising therapeutic strategy for CNS diseases.
Insights
Microglia, the immune cells of the central nervous system, change their function based on metabolism. Targeting their glucose metabolism offers a new way to treat neurological disorders.
Area of Science:
- Neuroscience
- Immunology
- Metabolic pathways
Background:
- Microglia are key immune cells in the central nervous system (CNS) involved in neurological disorders.
- Microglial plasticity allows diverse phenotypes driven by microenvironmental cues.
- Metabolic reprogramming, especially glucose metabolism, critically regulates microglial polarization and function.
Purpose of the Study:
- To review microglial polarization and glycolytic reprogramming in neurological diseases.
- To explore the role of metabolic reprogramming in CNS pathologies.
- To highlight the need for further research into microglial metabolomics and epigenetics.
Main Methods:
- Literature review of microglial polarization.
- Analysis of metabolic reprogramming in CNS disorders.
- Exploration of glycolytic pathways in microglial function.
Main Results:
- Microglial polarization is tightly linked to glucose metabolic reprogramming.
- Proinflammatory microglia primarily use glycolysis; anti-inflammatory microglia use oxidative phosphorylation.
- Targeting microglial glycolysis is a potential therapeutic strategy for CNS diseases.
Conclusions:
- Microglial metabolic reprogramming is central to their role in neurological disorders.
- Modulating microglial metabolism, particularly glycolysis, may offer novel therapeutic strategies.
- Further investigation into the interplay of metabolomics and epigenetics in microglia is warranted.
Related Concept Videos
Ligand-gated Ion Channels
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Drugs Affecting Neurotransmitter Synthesis
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Diabetic Neuropathy

